Please login to the form below

Not currently logged in
Email:
Password:

Germany launches USD 1.1bn initiative to boost pharmaceutical research

Germany launches a USD 1.1bn initiative to boost pharmaceutical R&D in the region.

According to local media reports, Germany has launched an initiative to boost pharmaceutical R&D in the region.

The new 'Pharma-Initiative' has a budget of EUR 800m (USD 1.1bn) and will run until 2011.

Germany's declining pharmaceutical sector has been highlighted by studies which have demonstrated that only a small percentage of approved pharmaceuticals are produced by German pharmaceutical firms. Innovation is largely driven by the US, the UK and Switzerland.

According to the Ministry for Research and Education, the new initiative will augment the innovation capacity of the pharmaceutical sector and promote pharmaceutical production concepts which unite the whole value chain, from the research laboratory right through to the production stage.

The mainstay EUR 100m-fund is called ìBioPharma: the strategy competition for the medicine of the futureî. Business-led consortia have been invited to suggest strategic concepts, which will see biopharmaceutical innovations through from research to application.

The German government is focusing on consortia which want to establish enduring links between the different stages of the process, most of which will be performed in Germany.

Germany is the third largest pharmaceutical market in the world and is the largest in Europe. Although the domestic consumption of pharmaceuticals is being constrained by government policy, the export market continues to expand. Germany also has the largest generic market in the EU. According to a PMLive Focus on Germany report, spending on drugs was EUR 23.4bn, while per capita health spending was EUR 2,900.

30th July 2007

Share

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Viseven

Viseven is a full cycle digital agency with 10 years expertise in developing content for the global pharmaceutical market delivering...

Latest intelligence

OPEN Health at the World Orphan Drug Conference USA
Our Director of Rare Disease, Gavin Jones looks forward to his conversation with Emily Crossle & Betsy Bogard at #WODCUSA2020 !...
Can involving patients in design transform the clinical trial experience?
While the research space is a heavily regulated environment and there are rules that we must abide by, this doesn’t mean clinical study materials have to be ‘boring’ or the...
Planning your clinical trial? Why you need to engage patients sooner
It’s highly likely that clinical studies are deterring patients based on decisions made in the early stages, such as during planning and design....

Infographics